Long-acting injectable buprenorphine (1st gen Sublocade; 2nd gen Brixadi) can improve medication adherence, treatment retention, quality of life, and treatment satisfaction for patients with OUD.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
